Materials and methods

Biochemical identification and culture
Colonies that were identified as C. pseudotuberculosis according to cultural and morphological examination were subjected to the biochemical tests described by Winn et al. (15) .
Verification of PLD gene by PCR
C. pseudotuberculosis DNA extraction was performed using a Wizard Genomic DNA Purification Kit (Promega, USA) according to the manufacturer's instructions. The PCRs were performed with PLD-F and PLD-R1 primers according to Pacheco et al. (16) (Table) . The PCR product was electrophoresed in a 1% (W/V) agarose gel in 1X Trisacetic acid-EDTA buffer (81 mM Tris base, 18.87 mM acetic acid, 1 mM EDTA) and a 100-bp DNA ladder was used (Sigma-Aldrich, Germany).
Amplification of PLD gene for cloning
The CLON-F1 and CLON-R1 primers are specific to the PLD gene of C. pseudotuberculosis isolated from infected sheep based on the available genome sequence in the NCBI GenBank Database (accession number L16587.1) (Table) . Each PCR reaction included 1X PCR buffer (with KCl), 1.5 mM MgCl 2 , 0.2 mM dNTP, 0.4 mM of each primer, 0.04 U of Taq DNA polymerase, and 10 ng/µL template DNA; ultrapure water was added to obtain a final volume of 50 µL. Thermal cycling was performed according to Pacheco et al. (16) . The size of the PCR products was verified by comparison with a 100-bp DNA ladder (Sigma, Germany) and a 1-kb DNA ladder (Fermentas, USA) in agarose gel. PCR cycling was carried out according to Pacheco et al. (16) . The PCR product was then purified using a GenElute Gel Extraction Kit (Sigma-Aldrich, Germany), and the pure PCR product was cloned using a Champion pET SUMO Protein Expression System (Invitrogen, USA).
Verification of ligated pET SUMO vector
Plasmids from randomly selected recombinant colonies on agar were isolated using a GenElute Plasmid Miniprep Kit (Sigma-Aldrich, Germany) according to the manufacturer's protocol. The recombinant plasmid was verified by PCR, restriction enzyme digestion (Thermo Scientific, USA), and sequence analysis using PLD CPF, PLD CPR, SUMO Forward, and T7 Reverse primers (Table) . The sequencing was performed in another laboratory (BM Metabion, Turkey). The results were analyzed using the LALIGN EMBL-EBI program. The amino acid sequences were compared using the Clustal 2.1 Multiple Sequence Alignment program.
Expression of recombinant PLD in One Shot®BL21(DE3) Escherichia coli
The confirmed recombinant colony was incubated in LB medium with 50 µg/mL kanamycin at 37 °C for 16 h and the first culture was prepared. The first culture (1/10) was incubated in TY medium (17) with 50 µg/mL kanamycin at 37 °C and 200 rpm until optical density (OD) 550 = 0.6-0.8. Then medium was added so that the final concentration of IPTG (AppliChem, Germany) reached 0.1 mM, and it was incubated in a water bath for 4 h at 30 °C and 200 rpm (11, 17) . The control culture was treated by the same protocol without IPTG.
Determination of protein solubility
To determine whether the protein was soluble or insoluble, protein profiles were examined by sodium dodecyl sulfatepolyacrylamide gel electrophoresis (SDS-PAGE) using the Laemmli protocol (18) . Approximately 50 µg of protein was loaded into each lane, and the resolving gels were run for 2.5 h at 150 V. The gels were then dyed with Coomassie Brilliant Blue R-250 (AppliChem, Germany) using the protocol of Sambrook and Russell (19) , and the proteins were verified with unstained protein marker (Thermo Scientific, USA).
Western blotting
The protein samples were electrophoretically separated by SDS-PAGE and transferred to a nitrocellulose membrane (Bio-Rad, USA). Western blotting was performed using A reverse CAMP test was used to measure the activities and titers of the concentrated rPLD and dPLD (20, 21) . For the synergistic hemolytic assay, 100-µL samples of the rPLD and dPLD were diluted 2-fold in sterile physiological saline (NaCl, 9 g in 1 L), and then 100 µL was inoculated into a hole on an agar base with 5% sheep blood agar plate and synergistic hemolytic efficiencies were determined with Rhodococcus equi.
Results
Verification and amplification of the PLD gene
The sections of the PLD gene amplified with PLD-F/ PLD-R1 and CLON-F1/CLON-R1 primers appear as 203-bp and 924-bp fragments, respectively (Figures 1 and 2) . The expected size of the pET SUMO vector ligated with the PLD gene is 6567 bp, as shown in Figure 3 , lane 1. When the recombinant colonies were digested with SspI, samples 1 and 4-6 displayed the expected 4722-bp, 1278-bp, and 567-bp restriction products on agarose gel ( Figure 4) ; the samples in lanes 2 and 3 were not the correct recombinant colonies, as indicated by the incorrectly sized restriction products.
Verification by bioinformatic methods for data analysis
The comparison of the rPLD gene with the gene in the NCBI GenBank database revealed 99.7% sequence similarity; differences were noted at the 448th and 449th bases, corresponding to differences at the 181st and 307th amino acids in sequences of the NCBI dPLD and rPLD gene products.
Determination of the amount of soluble/insoluble protein
Soluble dPLD (33.8 kDa), soluble rPLD (45 kDa), pET SUMO fusion protein (11 kDa), and other intracellular and extracellular proteins were detected by SDS-PAGE and western blot. The amounts of concentrated and unconcentrated rPLD were compared with SDS-PAGE (Figures 5 and 6 ).
Determination of hemolytic activity
The amounts of soluble dPLD and rPLD concentrated using an ultramembrane cassette system were measured as 23.6 mg/mL and 23.1 mg/mL, respectively. The hemolytic activities of concentrated soluble dPLD and rPLD were 1/256 and 1/256 as measured by the reverse CAMP test (Figures 7 and 8 ).
Discussion
Exotoxin samples belonging to different C. pseudotuberculosis isolates are reported to be similar antigenically (22, 23) . Differences have been noted between strains with respect to the amount of toxin and the size of the lesions (24) . Various studies have characterized and examined the structure of natural and recombinant PLD exotoxins (7, 21, 25) .
In this study, rPLD was produced using a pET SUMO vector, a TA cloning system, One Shot®BL21(DE3) E. coli, TY medium, and an ultramembrane cassette system. This protocol differs from those previously used to produce rPLD (25) (26) (27) . Soluble rPLD was expressed using this protocol, in contrast with some other studies (25, 27) but similar to the results reported by Songer et al. (26) . However, Songer et al. found that the enzyme activity of the C. pseudotuberculosis culture supernatant was approximately 2.5-fold more effective than that of E. coli (pCpO5O). These results differ from our study; we found similar protein concentrations and hemolytic activities for soluble rPLD and dPLD as measured by a BCA protein assay and a reverse CAMP test, respectively. This may be due to the specific medium, incubation temperature, and final concentration of IPTG we chose as well as the use of a SUMO fusion protein system for the production of soluble recombinant protein. These findings are consistent with those of other researchers (17, 28, 29) .
The amino acid sequence differences between dPLD and rPLD produced in this study and the protein in the NCBI database (a valine instead of a tyrosine at position 181 and the lack of a tryptophan at position 307) are likely due to differences in the PLD gene of C. pseudotuberculosis isolated from the field or were introduced by Taq polymerase during cloning. The hemolytic titers and the amount of concentrated rPLD and dPLD suggest that these sequence changes do not affect the functionality of the enzymes. Previous studies have not provided a similar characterization of rPLD and dPLD.
Our results suggest that the composition of medium, incubation temperature, final IPTG concentration, cloning method, and the type of promotor, fusion protein, and vector affect the amount of soluble rPLD that can be produced and that the ultramembrane cassette system may be useful for concentration of recombinant proteins under laboratory conditions. 
